drugset
drugset / Trial / NCT00969410

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

NCT00969410 ↗

Phase 1 Completed 19 enrolled AVEO Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases. To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid tumors who have liver metastases.

Timeline

Start
2009-08
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ficlatuzumab Monoclonal antibody 2 mg/kg Intravenous
Subject Ficlatuzumab Monoclonal antibody 10 mg/kg Intravenous
Subject Ficlatuzumab Monoclonal antibody 20 mg/kg Intravenous

Indications

cancer